Aquestive Therapeutics (NASDAQ:AQST) SVP Melina Cioffi Sells 25,311 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) SVP Melina Cioffi sold 25,311 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total transaction of $105,546.87. Following the completion of the sale, the senior vice president owned 274,867 shares of the company’s stock, valued at approximately $1,146,195.39. This trade represents a 8.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Aquestive Therapeutics Trading Down 4.3%

Shares of AQST stock traded down $0.18 during trading hours on Thursday, reaching $4.09. 574,749 shares of the company’s stock were exchanged, compared to its average volume of 5,516,916. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.12 and a fifty-two week high of $7.55. The stock’s 50 day moving average is $4.08 and its 200-day moving average is $5.21. The company has a market cap of $498.66 million, a price-to-earnings ratio of -5.28 and a beta of 1.61.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The firm had revenue of $13.02 million during the quarter, compared to analysts’ expectations of $13.28 million. Equities analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on AQST shares. Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Finally, Lake Street Capital set a $6.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $8.80.

Aquestive Therapeutics News Summary

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright raised several near‑term EPS estimates and lifted its FY2026 view (less negative) — modest analytical support for the story and potential relief if guidance/progress continues. HC Wainwright Estimates
• Positive Sentiment: Independent coverage remains constructive on Anaphylm: a Seeking Alpha piece reiterates a Buy and argues the CRL issues are addressable (packaging/labeling), forecasting a high approval/adoption probability if the planned PK study succeeds. That supports upside tied to regulatory progress. Seeking Alpha: Anaphylm
• Neutral Sentiment: Short‑interest data in feeds is currently reporting anomalous/zero values (likely data error) and should not be relied on for a short‑squeeze narrative until official reporting clears up. (No reliable link.)
• Negative Sentiment: Multiple law firms and notice filings indicate a securities class action has been filed and several firms are soliciting lead‑plaintiff roles for purchasers from June 16, 2025 to Jan 8, 2026 — this increases legal exposure, potential costs, and investor uncertainty. Representative notices: Bernstein Liebhard, Rosen, Portnoy/others. Bernstein Liebhard Alert Portnoy Notice
• Negative Sentiment: A PRNewswire item highlights a lawsuit alleging an analyst (Cantor) slashed AQST’s price target from $15 to $8 (Jan 9), linking that cut to a >37% one‑day loss for certain holders — adds a contested narrative about analyst conduct and market impact. PR Newswire: Analyst Lawsuit
• Negative Sentiment: Large insider sales were disclosed on March 10 (CEO and multiple senior officers sold sizeable blocks at ~ $4.17), reducing insider ownership materially — often interpreted by markets as a negative signal about near‑term prospects or liquidity needs. Representative SEC filing (CEO): SEC Filing (CEO Sale)

Institutional Investors Weigh In On Aquestive Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. NewEdge Advisors LLC purchased a new stake in Aquestive Therapeutics in the third quarter valued at approximately $28,000. BNP Paribas Financial Markets increased its holdings in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after buying an additional 4,134 shares during the period. Modern Wealth Management LLC purchased a new position in Aquestive Therapeutics during the 2nd quarter worth approximately $33,000. Cox Capital Mgt LLC acquired a new stake in Aquestive Therapeutics during the 3rd quarter valued at approximately $59,000. Finally, Kestra Private Wealth Services LLC acquired a new stake in Aquestive Therapeutics during the 3rd quarter valued at approximately $60,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.